Key points (3).
• NTRK inhibition (larotrectinib) has a high added therapeutic value and constitutes an unsatisfied medical therapeutic need. • There are no studies that have evaluated (locally or internationally) the cost-effectiveness of larotrectinib. However, the clear clinical benefit for diverse rare tumors that carry the NTRK1–3 fusion gene constitutes a balanced strategy for different sanitary models on a global scale. |